ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,064.20
      0.91%
      US Tech 100
      17,173.20
      1.85%
      Dow Jones
      38,225.66
      0.85%
      Brent Oil
      83.945
      0.38%
      Bitcoin
      59,045.52
      -0.13%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Avalo Therapeutics Inc (AVTX)

      7. Avalo Therapeutics Inc (AVTX) News

      AVTX

      Avalo Therapeutics (AVTX)

      Avalo Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:AVTX
      DateTimeSourceHeadlineSymbolCompany
      2:07PMiHub NewswireFeaturedNanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
      04/02/20247:00AMGlobeNewswire Inc.Avalo Therapeutics Appoints Biotech Leaders to Board of DirectorsNASDAQ:AVTXAvalo Therapeutics Inc
      03/29/20244:01PMGlobeNewswire Inc.Avalo Reports 2023 Financial Results and Provides Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
      03/27/20244:01PMGlobeNewswire Inc.Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 MillionNASDAQ:AVTXAvalo Therapeutics Inc
      02/14/20249:13PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
      02/14/202410:02AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
      01/31/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
      12/28/20235:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
      12/27/20237:00AMGlobeNewswire Inc.Avalo Therapeutics Announces 1-for-240 Reverse Stock SplitNASDAQ:AVTXAvalo Therapeutics Inc
      12/21/20234:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTXAvalo Therapeutics Inc
      12/21/20234:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTXAvalo Therapeutics Inc
      12/20/20234:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
      12/07/20237:02AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AVTXAvalo Therapeutics Inc
      12/07/20237:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
      12/07/20237:00AMGlobeNewswire Inc.Avalo Encourages Stockholders to Vote FOR the Reverse Stock SplitNASDAQ:AVTXAvalo Therapeutics Inc
      11/16/20237:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
      11/09/20237:21AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVTXAvalo Therapeutics Inc
      11/09/20237:04AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
      11/09/20237:00AMGlobeNewswire Inc.Avalo Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
      10/31/20237:21AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
      10/31/20237:00AMGlobeNewswire Inc.Avalo Completes Divestiture of AVTX-800 SeriesNASDAQ:AVTXAvalo Therapeutics Inc
      10/19/20234:15PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:AVTXAvalo Therapeutics Inc
      10/19/20234:06PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AVTXAvalo Therapeutics Inc
      10/19/20234:01PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AVTXAvalo Therapeutics Inc
      10/17/20234:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
      10/05/20234:02PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:AVTXAvalo Therapeutics Inc
      09/26/20237:04AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
      09/26/20237:00AMGlobeNewswire Inc.Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and InnovationNASDAQ:AVTXAvalo Therapeutics Inc
      09/13/20234:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
      09/13/20239:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:AVTX